JP2022502434A5 - - Google Patents

Info

Publication number
JP2022502434A5
JP2022502434A5 JP2021517299A JP2021517299A JP2022502434A5 JP 2022502434 A5 JP2022502434 A5 JP 2022502434A5 JP 2021517299 A JP2021517299 A JP 2021517299A JP 2021517299 A JP2021517299 A JP 2021517299A JP 2022502434 A5 JP2022502434 A5 JP 2022502434A5
Authority
JP
Japan
Prior art keywords
antagonist
weeks
sfrp2
pharmaceutical composition
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021517299A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022502434A (ja
JP7451506B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/053651 external-priority patent/WO2020069439A1/en
Publication of JP2022502434A publication Critical patent/JP2022502434A/ja
Publication of JP2022502434A5 publication Critical patent/JP2022502434A5/ja
Application granted granted Critical
Publication of JP7451506B2 publication Critical patent/JP7451506B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021517299A 2018-09-27 2019-09-27 がんの治療用の薬学的組合せ Active JP7451506B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862737155P 2018-09-27 2018-09-27
US62/737,155 2018-09-27
PCT/US2019/053651 WO2020069439A1 (en) 2018-09-27 2019-09-27 Pharmaceutical combination for the treatment of cancer

Publications (3)

Publication Number Publication Date
JP2022502434A JP2022502434A (ja) 2022-01-11
JP2022502434A5 true JP2022502434A5 (cg-RX-API-DMAC10.html) 2022-10-05
JP7451506B2 JP7451506B2 (ja) 2024-03-18

Family

ID=69953118

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021517299A Active JP7451506B2 (ja) 2018-09-27 2019-09-27 がんの治療用の薬学的組合せ

Country Status (12)

Country Link
US (1) US20210395351A1 (cg-RX-API-DMAC10.html)
EP (1) EP3856784A4 (cg-RX-API-DMAC10.html)
JP (1) JP7451506B2 (cg-RX-API-DMAC10.html)
KR (1) KR102947706B1 (cg-RX-API-DMAC10.html)
CN (2) CN119818670A (cg-RX-API-DMAC10.html)
AU (1) AU2019351267B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021005525A2 (cg-RX-API-DMAC10.html)
CA (1) CA3114173A1 (cg-RX-API-DMAC10.html)
IL (1) IL281782A (cg-RX-API-DMAC10.html)
MX (1) MX2021003274A (cg-RX-API-DMAC10.html)
SG (1) SG11202102865WA (cg-RX-API-DMAC10.html)
WO (1) WO2020069439A1 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021013222A (es) * 2019-05-03 2022-01-06 Genentech Inc Metodos para tratar el cancer con un anticuerpo anti-pd-l1.
WO2025199292A1 (en) * 2024-03-21 2025-09-25 Musc Foundation For Research Development A humanized monoclonal antibody to sfrp2 for tumor associated macrophage reduction and polarization in cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2285989B1 (en) 2008-05-15 2016-11-16 The University of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
WO2011119524A1 (en) 2010-03-22 2011-09-29 The University Of North Carolina At Chapel Hill Novel targets for regulation of angiogenesis
WO2014022774A1 (en) 2012-08-02 2014-02-06 Fred Hutchinson Cancer Research Center Treatment induced damage to the tumor micro-environment promotes cancer therapy resistance through extracellular proteins
EP3313441B1 (en) * 2015-06-24 2024-02-21 Janssen Biotech, Inc. Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
HK1254404A1 (zh) * 2015-06-25 2019-07-19 Advanced Accelerator Applications 治疗过度表达生长抑素受体的神经内分泌肿瘤的方法
WO2017024465A1 (en) 2015-08-10 2017-02-16 Innovent Biologics (Suzhou) Co., Ltd. Pd-1 antibodies
CA3001131A1 (en) 2015-11-02 2017-05-11 Five Prime Therapeutics, Inc. Cd80 extracellular domain polypeptides and their use in cancer treatment
PL3964529T3 (pl) * 2016-01-22 2025-10-27 MabQuest SA Nieblokujące przeciwciała specyficzne względem pd1
CN110267682A (zh) * 2017-02-14 2019-09-20 诺华股份有限公司 Wnt抑制剂和抗PD-1抗体分子组合的给药方案

Similar Documents

Publication Publication Date Title
DE69932600T2 (de) Zusammensetzungen und verfahren zur behandlung von tumoren
Lewis Phillips et al. Trastuzumab uptake and its relation to efficacy in an animal model of HER2-positive breast cancer brain metastasis
US20020076408A1 (en) Combination radiation therapy and chemotherapy in conjunction with administration of growth factor receptor antibody
JP2022513685A5 (cg-RX-API-DMAC10.html)
JP2003520195A (ja) 上皮成長因子受容体アンタゴニストによる難治性ヒト腫瘍の処理
CN109153724A (zh) 通过施用pd-1抑制剂治疗皮肤癌的方法
MXPA02011194A (es) Inhibidores de aromatasa y anticuerpos anti-her2 monoclonales como agentes antitumorales.
WO2019096194A1 (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
JP2012136535A (ja) 癌治療のためのrhuMAbHER2と組み合わせたドセタキセル
AU2018101488A4 (en) Method and kit for treating cancer through combination therapy
WO2021182573A1 (ja) 癌の治療及び/又は予防のための医薬品
JP2025060639A (ja) Pd-1/pd-l1シグナル伝達阻害剤に不応答性のがんの処置方法および医薬
DE60316106T2 (de) Gemeinsamer lymphatischer endothel- und gefässendothel-rezeptor-1 (clever-1) und seine verwendung
CN109476733A (zh) 使用il-17拮抗剂治疗新发斑块型银屑病的方法
DE69837322T2 (de) Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
WO2021182572A1 (ja) 癌の治療及び/又は予防のための医薬品
CN113318226A (zh) 抗pd-l1抗体联合放射性射线治疗肺癌的方法
JP2023537115A5 (cg-RX-API-DMAC10.html)
KR20240168479A (ko) 건선 치료 방법
EP4115902A1 (en) Combined use of ctb006 and ponatinib
CN118076377A (zh) 人类表皮生长因子第二型受体疫苗组成物
Gaustad et al. Properdistatin inhibits angiogenesis and improves vascular function in human melanoma xenografts with low thrombospondin-1 expression
Zhang et al. A phase I study of Hemay022, an irreversible dual EGFR/HER2 tyrosine kinase inhibitor in Chinese patients with HER2-positive advanced breast cancer
EP3976037A1 (en) Compositions and methods to treat cancer
KR102834430B1 (ko) 전신 투여용 종양용해성 단순 포진 바이러스를 포함하는 약학적 조성물